Why GLP-1 Weight Loss Can Slow

Weight loss progression on GLP-1 medications like semaglutide and tirzepatide often slows due to complex hormonal interactions with concurrent diabetes treatments. While semaglutide mimics natural hormones to reduce appetite and tirzepatide adds GIP to maintain energy levels, the upcoming triple agonist ratatrutide introduces glucagon receptor activation to increase fat oxidation and energy expenditure. However, medications like sulfonylureas can hinder these effects by forcing the pancreas to release excess insulin, keeping the body in "storage mode" and triggering cravings that stall fat breakdown. In contrast, metformin generally complements GLP-1 therapy by improving insulin sensitivity without causing the same storage interference. Effective metabolic management requires clinical oversight to adjust or discontinue insulin-stimulating drugs, ensuring the hormonal environment shifts from energy storage to active fat burning for sustainable results.